Unveiling Mechanisms of MRTX1133 Resistance
Recent years have seen major advances in KRAS G12D-targeted therapeutics. However, acquired drug resistance remains a significant clinical challenge, with underlying mechanisms still not fully understood. At AACR 2026, WuXi Biology presented a poster highlighting the establishment of MRTX1133-resistant GP2D (colorectal) and KPC (pancreatic) tumor models to investigate KRAS G12D inhibitor resistance.
The authors show that these models maintained stable resistance phenotypes to MRTX1133 both in vitro and in vivo, and exhibited broad cross-resistance to additional KRAS G12D inhibitors. Integrated bioinformatic and western blot analyses further revealed convergent resistance mechanisms. These models may support biomarker discovery and the development of rational combination strategies to overcome KRAS G12D inhibitor resistance.
Poster_AACR 2026_Unveiling Mechanisms of MRTX1133 Resistance in PDAC Models
Related Content
Small cell lung cancer (SCLC) remains one of the most aggressive and difficult-to-treat cancers, highlighting the ongoing need for new...
VIEW RESOURCEAntibody-drug conjugates (ADCs) have emerged as an important modality in targeted cancer therapy development. However, acquired resistance continues to limit...
VIEW RESOURCE